Afqlir

Afqlir is a pharmaceutical product containing Aflibercept, used for intravitreal administration. It is designed to address specific eye conditions by targeting vascular endothelial growth factor (VEGF).

Afqlir is primarily used for intravitreal administration to manage certain eye conditions related to abnormal blood vessel growth. It works by inhibiting vascular endothelial growth factor (VEGF), which can help reduce swelling and leakage in the retina. This medication is often considered for conditions where excessive blood vessel growth in the eye is a concern.

Common effects of Afqlir may include temporary vision disturbances, eye redness, or discomfort at the injection site. Some users might experience mild irritation or inflammation following administration. These effects are generally short-lived and should be monitored by a healthcare professional.

Afqlir should be handled with care and administered by a qualified healthcare professional. It is important to follow proper aseptic techniques to minimize the risk of infection. Patients should be monitored for any signs of adverse reactions, and the medication should be stored as directed to maintain its efficacy.

Afqlir may interact with other medications, particularly those that affect blood clotting or immune response. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain supplements might also influence the effectiveness or safety of Aflibercept.